If you want to understand the current schizophrenia of the global pharmaceutical industry, you only need to look at two entirely different approaches to “radically improving patients’ lives” playing out right now.
On one end of the spectrum, we have the high-gloss, Silicon Valley-adjacent promises of US biotech. Take Recursion Pharmaceuticals Inc (NASDAQ: RXRX) as a prime example. Sitting on a market cap of around $1.71 billion, despite trading at a modest $3.23 a share and carrying a rather hefty short interest of roughly 33%, Recursion is selling the future. They are literally trying to decode biology. Their game plan involves smashing together chemistry, data science, automation, and engineering to completely industrialise drug discovery. It’s heavily US-centric, undeniably clever, and attracts massive capital. But while the Global North pours money into these automated, AI-driven pipelines, the actual reality of accessing life-saving interventions on the ground is a whole different ball game.
Enter Beximco Pharmaceuticals, operating out of Bangladesh. They’ve just thrown a massive spanner in the works of Big Pharma’s traditional pricing models. In a recent handover ceremony in Dhaka, the first patients globally collected their batches of a generic version of the cystic fibrosis (CF) wonder-drug ETI (Elexacaftor/Tezacaftor/Ivacaftor). You’d probably know the original formulation under Vertex Pharmaceuticals’ brand names, Trikafta or Kaftrio.
Vertex has been pulling in unprecedented profits off a monopoly price tag that sits somewhere around $370,000 per patient, per year in the States. That kind of exorbitant pricing is completely out of reach for most of the world. It’s left tens of thousands of kids and young adults with CF essentially waiting to die, locked out of a cure by a paywall. CF is a hectic, life-shortening genetic disease where thick mucus destroys lung function and the digestive tract. Without treatment, many don’t see their second birthday, and in vast stretches of the developing world, reaching adulthood is just a pipe dream.
But Beximco’s generic, branded as ‘Triko’, is changing the landscape entirely. Pricing the medication at $12,750 a year for adults and $6,375 for kids, they’ve managed a 96% price drop compared to the US list price. Patients from Slovakia, Qatar, the US, the UK, Bangladesh, and right here in South Africa were among the first to get their hands on it. It’s the culmination of years of hard graft by the grassroots Right to Breathe campaign, fighting tooth and nail for universal access to CF modulators.
How they bypassed the patent is a masterclass in making a plan with international trade law. Bangladesh is classified by the UN as a Least Developed Country (LDC). Under the WTO’s TRIPS agreement, LDC member states are exempt from enforcing pharmaceutical patents. Beximco used this perfectly legal loophole to manufacture and export the generic. The development of this affordable alternative was publicly backed by a coalition of CF parents at the North American Cystic Fibrosis Conference in Seattle back in October 2025.
The sheer scale of the inequality they are trying to fix is staggering. There are about 160,000 diagnosed CF patients globally, and an estimated 80,000 more who are undiagnosed—the vast majority of whom are in low- and middle-income countries. To put the pricing into perspective, you can treat 58 kids on Triko for the exact same cost of putting one child on the branded drug.
And the innovation isn’t just happening in the manufacturing hubs; it’s happening in local clinics. South African CF doctors have actively developed a dose-reduction protocol that pulls the cost of treating a child down to under $2,000 a year. To widen the net even further, BEXDECO—a generic of just the Ivacaftor component—has been rolled out separately for $5 a pill for patients who only need that specific monotherapy.
Right now, the initial rollout is being managed on a patient-by-patient basis via the CF Buyers’ Club, with plans to scale up supply to the broader global CF community as production ramps up. You look at Recursion’s data pipelines promising to industrialise tomorrow’s cures, and then you look at Beximco leveraging LDC trade rules to get generic pills into dying patients’ hands today. It leaves you wondering which side of the industry is actually decoding the real problem.